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Background: Cancer is a severe threat to the human society. In the scientific community worldwide cancer
remains a big challenge as there are no remedies as of now. Cancer is quite complicated as it involves
multiple signalling pathways and it may be caused by genetic disorders. Various natural products and
synthetic molecules have been designed to prevent cell proliferation. Peptide-based anticancer drugs,
however, are not explored properly. Though peptides have their inherent proteolytic instability, they could
act as anticancer agents.
Results: In this present communication a suitably protected cystine based dipeptide and its deprotected form
have been synthesized. Potent anticancer activities were confirmed by MTT assay (a laboratory test and a
standard colorimetric assay, which measures changes in colour, for measuring cellular proliferation and phase
contrast images. The IC50 value, a measure of the effectiveness of a compound in inhibiting biological or
biochemical function, of these compounds ranges in the sub-micromolar level. The binding interactions with
serum albumins (HSA and BSA) were performed with all these molecules and all of them show very strong binding
at sub-micromolar concentration.
Conclusions: This study suggested that the cystine-based dipeptides were potential anticancer agents. These peptides
also showed very good binding with major carrier proteins of blood, the serum albumins. We are currently working on
determining the detailed mechanism of anticancer activity of these molecules.
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Cancer has been an ever-growing public problem
since its appearance and the estimated worldwide new
incidence of it is about 6 million cases per year [1-4].
It is the second major cause of death after cardiovascular
disease [5]. This disease is now well characterized by
unregulated proliferation of cells [6,7]. There has long
been a search for a therapeutic agent to inhibit or control
cell proliferation. Various natural products along with
synthetic molecules are continuously explored to achieve
development of a viable anticancer molecule [8-10].
Peptides are very versatile biological molecules. Except for
a few inherent problems, peptides or peptide-based* Correspondence: biswadip.banerji@gmail.com
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reproduction in any medium, provided the ormolecules are most bio-compatible [11,12]. Compared
with traditional treatments such as chemotherapy,
peptides with high specificity against cancer cells may
present an alternate way of killing cancer cells while
protecting normal cells [13]. Many natural or synthetic
peptides have been reported to show anticancer activity
[14]. Peptide-based (or peptide-derived) anticancer drugs
have the potential to selectively target and disrupt the
signalling pathways in the course of carcinogenesis [15].
In the present study, we have synthesized a few cystine
based dipeptide compounds (protected and deprotected
L-Cys-L-Cys, L-Cys-D-Cys, 1A-1D) (Figure 1). These
compounds show anticancer activity against different
cancer cell lines. In addition, we performed an interaction
study of them with serum albumins. In blood all the drugs
must bind with the serum albumins in order to reach the
target site [16-18]. Therefore, the study of serum proteinal Ltd. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The structures of cysteine derived dipeptide compounds. Where A corresponds to 1A, B corresponds to 1B, C corresponds to 1C
and D corresponds to 1D respectively.
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important [19-21]. In this paper we wish to disclose the
sub-micromolar anticancer activity of these peptides
and their binding interactions with serum albumins
(BSA and HSA). Cell viability assay was done by
MTT-assay while the binding studies were carried out
using fluorescence spectroscopy, circular diachroism,
molecular modelling and computational analysis. The low-
micromolar anticancer activity may be further improved by
changing different protection groups.
Experimental methods
Cell culture
Neura 2a (neuroblastoma cell line), Hek 293 (kidney cancer
cell line) and Hep G2 (liver cancer cell line) were procured
from the National Centre for Cell Sciences (NCCS,
Pune, India) and were grown in Dulbecco’s modified
Eagle medium antibiotics (penicillin/streptomycin and
gentamicin). Cells were cultured at 37°C in 95% air
and 5% CO2 humidified incubators. Hep G2 cells were
seeded at a density of 105 well plated in 96 well plates. Cells
were typically grown to 60–70% confluence, rinsed in
phosphate-buffered saline (PBS) and placed into serum-free
medium overnight prior to treatments. After over-
night incubation, the Hep G2, HEK 293, and Neura
2a cells were treated with these compounds separately
at the concentration of 1 μM, 10 μM and 20 μM,
respectively. After 48 hours the medium was removed and
a 50 μl of fresh medium was added along with 10 μl of
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide). MTT solution (5mg/ml) was slowly removed
after 4 hours and the purple crystals with solubilization in
1.4 ml of DMSO. The absorbance was measured at test
wavelength of 550 nm in Elisa Plate Reader [22,23].Fluorescence
The steady-state fluorescence spectra were recorded with
a Perkin Elmer LS-45 spectrofluorophotometer. Emission
spectra were recorded with an excitation wavelength of
280 nm and emission range of 290–450 nm. Both
the excitation and emission slit widths kept at 5 nm each.
The intrinsic fluorescence of tryptophan residue(s) in the
protein was measured in the presence and in the absence
of the dipeptides. Most of the experiment was carried out
at room temperature (25°C), Some temperature dependent
studies were carried out using water bath.
The fluorescence of the protein was found to quench
in the presence of the peptides. The quenching experiment
was carried out simply by adding small aliquote (1–10 μL
from 100 μM stock solution) of concentrated peptide
solution to 1 mL solution containing an appropriate
concentration of HSA/BSA (0.5 μM in 20 mM Tris–HCl
buffer, pH 7.5) taken in 1 cm path length quartz cuvette.
The optical density of the solution at the excitation wave-
length was kept less than 0.05. Small error due to dilution
upon addition of the peptide was neglected. The peptides
showed negligible absorbance at the excitation wavelength
(280 nm). Fluorescence intensities at 340 nm were recorded
as a function of ligand concentration. To derive the binding
parameters, obtained data were analyzed using modified
Stern–Volmer equation [24-26].
Measurements of circular dichroism (CD)
The Far-UV CD spectra have been measured on a Jasco
J-810 spectrometer using a 1.0 mm quartz cell under
constant nitrogen flow condition and at room
temperature. The CD spectra of HSA and BSA have
been recorded in the absence and presence of these
compounds within the wavelength range of 200–250
Banerji et al. Chemistry Central Journal 2013, 7:91 Page 3 of 10
http://journal.chemistrycentral.com/content/7/1/91nm. The CD results have been represented in terms of
ellipticity (θ).Docking
The crystal structure of HSA and BSA were obtained
from Protein Data Bank (PDB ID: 1E78 and 3V03
respectively). Structures of the synthesized compounds
were drawn in Gauss View followed by geometry
optimization in Gaussian 09 with DFT level of theory
using B3LYP/6-31 + G(d,p) basis set. AutoDock 4 and
MGLTools of The Scripps Research Institute were used to
perform the docking calculations [27,28]. Docking was
performed following the previously published protocol
[29-33]. The PyMOL molecular (http://pymol.org/) viewer
and the MGLTools were used to render the output.Results and discussion
Cell viability
In order to determine the biological efficacy of these
newly synthesized compounds in vitro cell culture
system has been used.
Cell viability was quantified by MTT, a yellow tetrazole
assay, where the viable cells were determined by the
reduction of the yellow MTT into purple formazan
product. For this assay, the cells were plated in 96 well
plates and grown in monolayer and then treated with
these compounds of interest. The viability of cells by
MTT assay was performed 48 hours post treatment as
described before. Finally, the medium was removed and
replenished with 80 μl of fresh medium along with 20 μl
of MTT (5 mg/ml). After 4 hours, MTT solution was
slowly removed and the purple crystals were solubilised
in 100 μl of DMSO. The absorbance was measured by a
plate reader at a wavelength of 550 nm. The absorbance
obtained from treated cells were expressed as percentages
of absorbance obtained from untreated cells and are
reported as mean ± SEM (n =3).Figure 2 Cytotoxicity studies against Neura 2a (2a), Hep G2 (2b), HekFor screening the activity, the cultured cells were
exposed to these compounds at three different concentra-
tions (1.0 μM, 10 μM and 20 μM) and incubated for 48
hours. Viability was assessed by MTT assay as described.
All the four compounds showed significant reduction in
the amount of viable cells in all the three cell lines
screened. The results are shown graphically below,
Figure 2a-c, respectively. From the bargraph it is observed
that these peptides cause significant reduction of viable
cells in this screening assay.
The compounds 1A and 1B show more cytotoxicity
than compounds 1C and 1D at a particular concentration.
Cytotoxiciy of 1A is comparable to 1B and the cytotoxicity
of 1C is comparable to 1D. Furthermore, cells were
also examined under an inverted phase contrast
microscope. For example, Hek 293 cells were treated
with these compounds (at 20.0 μM concentration)
for 24 hours and phase contrast micrographs were
taken. As shown in Figure 3, there was massive cell
death in response to these two compounds (1A and 1C)
as compared to control.
Action of a drug molecule to a cell is initiated by drug
receptor and many of the receptors have high specificity
for a drug molecule and the chemical structure of a drug
may significantly alter the cell's response to the drug
molecule. Also the concentration of drug molecule to
the receptor site directly affects the drug response. For
example, amphetamine and methamphetamine act as
powerful stimulus for nervous system and act via the
same receptor. These two compounds differed slightly in
their chemical structure; however, methamphetamine
exerts more powerful action. There are small structural
changes present in our synthesized dipeptides. NH2
groups in 1A and 1B are protected with carbamates, also
the carboxylic acid moiety is as a methyl ester. The
receptor that initiates the drug action of the dipeptides
may show difference in action due to these structural
changes. However, similar to many chemical reactions,293 (2c), cell lines presented respectively.
Figure 3 Phase contrast images showing cell death with compounds 1A and 1C at 20.0 μM concentration.
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concentration of the drug molecule at the receptor site.
Amount of drug that penetrates to the cell/receptor site
again depends on structure of the drug molecule and
their physical parameter such as hydrophobicity. One
possible explanation is that 1A and 1B (cLogP: 4.01, see
Additional file 1: Computation of partition coefficient
(cLogP)) are more hydrophobic than 1C and 1D (cLogP:
1.75). So, the membrane permeability of these two are
more than the other two. So, 1A and 1B can penetrateFigure 4 Effect of the compounds on the intrinsic fluorescence of ser
of compound 1C and 1D respectively with concentration varying from 0 μ
function of compound 1C and 1D respectively with concentration varying
maximum was observed. Excitation maximum, 280 nm; excitation and emithe cells better than that of 1C and 1D and could be
sensed by the receptor more strongly apart from the
structural specificity.
Cell viability tests were performed using cultured cells.
However, in real systems, like cells in human body/other
animals drugs need to be reached to the body/effected
cells by blood. All the drug molecules that enter into the
body via systemic circulation get exposed to the blood
milieu. In blood, serum protein albumins (HSA, BSA)
are the major carrier proteins. They bind to a wideum albumins. Here A and B are Emission spectra of HSA as a function
M to 5 μM (10 steps). Figure C and D are Emission spectra of BSA as a
from 0 μM to 5 μM (10 steps). About 4 to 6 nm blue shift in emission
ssion slit 5 nm each.
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them to different parts of the body. Very good binding
to these proteins means very good distribution of the
drug all over the body i.e., increased bioavailability.
Therefore, the binding behaviour of the synthesized
peptides to HSA and BSA was carried out using the
unique and intrinsic fluorescence from the tryptophan
residues. The dipeptides showed very good binding
with plasma carrier proteins of both bovine and
human. Interaction site of the peptides to the protein
was established via molecular docking analysis as
discussed later.
Binding constant from fluorescence study
The fluorescence spectra of HSA / BSA were measured
in the presence and absence of cystine based dipeptide
compounds. HSA shows a strong fluorescence with a
emission peak at ~340 nm due to its single tryptophan
residue (Figure 4). BSA with two tryptophan residues
showed similar fluorescence behavior, however, with
higher intensity due to the presence of two tryptophan
residues in BSA. Cystine based dipeptides (1A, 1B, 1C
and 1D) showed no intrinsic fluorescence in solu-
tion. However, their (compounds 1A, 1B, 1C and
1D) individual presence in the solution effectivelyFigure 5 Modified Stern-Volmer plot. (A) and (B) for BSA with compoun
and 1D, respectively.reduced fluorescence yield of HSA / BSA (slight blue
shift, ~ 4 nm of the fluorescence emission, was
within the band width of the measurement). The
fluorescence intensity at 340 nm decreased gradually
with increasing peptide concentration, indicating
effective fluorescence quenching of the protein fluor-
escence. Figure 4 shows the spectra in the presence
of different concentrations of these dipeptide com-
pounds 1C and 1D with HSA and BSA respectively.
The quenching spectra for 1A and 1B with HSA and
BSA are shown in Additional file 1: Figure S1.
Fluorescence data in the above experiments can be
analyzed using a modified Stern-Volmer (S-V) equa-
tion [24] (equation 1). Fluorescence peak intensity
values of the protein at different concentration of the









Where F0 is the fluorescence intensity in the absence
of an external quencher, ΔF is the difference in fluores-
cence in the absence and presence of the quencher at
concentration [Q], K is the Stern–Volmer quenchingds 1C and 1D, respectively. (C) and (D) for HSA with compound 1C
Table 1 Stern-Volmer quenching constant (K) with HSA
and BSA at temperature 298 K as obtained from
equation 1
Compounds Stern-Volmer quenching constant (M-1)
HSA BSA
1A 18.37 × 105 7.95 × 105
1B 4.32 × 105 3.52 × 105
1C 9.56 × 105 4.88 × 105
1D 10.97 × 105 5.90 × 105
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which is accessible to the quencher. The plots of F0/ΔF
versus 1 / [Q] (Figure 5) yields f −1 as the intercept, and
(f K)−1 as the slope. Table 1 shows the result. The inter-
cept on y axis (f-1) indicated that ~70-90% of the total
HSA fluorescence and ~50% of BSA fluorescence was
accessible for the quenchers (dipeptides). It also suggests
that only one tryptophan of BSA was accessible to the
quencher. Further temperature dependent experiment
showed that quenching constant for all the dipeptides
decreased with increasing of temperature (Additional file 1:
Table S1). This fact implied that the fluorescence
quenching of the protein solution by the peptides was
dominated by static quenching mechanism [24-26]. High
accessibility of the quencher and the decrease of quenching
constant indicated static fluorescence quenching and this
static quenching arose from the formation of a dark
complex between protein and dipetides [24,25]. The S-V
quenching constant as obtained from the modified S-V
equation can be shown to be the binding affinity constant,
Ka (Additional file 1: Fluorescence Study) [24]. Reciprocal
of this Ka gives the dissociation constant, Kd (Table 2).
Contribution of dynamic quenching due to diffusion
and collision of the peptides might be negligible as
we observed that accesiblity of the peptides to the
fluorphore (tryptophan residue in the protein) was
high (70-90% for HSA and ~ 50% as explained earlier). We
observed negligible amount of fluorescence quenching of
free tyrptophan in the presence of the dipeptide solution
(Additional file 1: Figure S3). This observation added
additional support that the quenching of the proteinTable 2 Binding dissociation constants (Kd) with HSA and
BSA at temperature 298 K
(SEM = standard error of
mean; NA = not available)
Compounds
Binding constant (Kd) ± SEM in μM
HSA BSA
1A 0.546 ± 0.05 1.257 ± NA
1B 2.312 ± NA 2.840 ± NA
1C 1.044 ± 0.08 2.051 ± NA
1D 0.912 ± NA 1.703 ± 0.07fluorescence by dipeptides was largely due to association
of the dipeptides close to the tryptophan residue in
the protein. It supported the view that the peptides
may be incorporated close to the tryptophan residue in the
proteins and formed a close association (dark complex)
and quenched fluorescence [26].
There is the same relationship between 1A and 1B that
between 1C and 1D: diastereoisomers. However, all the
four compounds showed similar binding efficiency
(Tables 1 and 2). It indicated that both the conformations
are equally significant in the attenuation of HSA/BSA
fluorecence. Eftink et. al. and others clearly indicated
how the quenching volume and the entry of the
quencher to the hydrophobic protein pocket influence
both the static and dynamic quenching [24-26]. As in
this investigation no significant difference occurred in
quenching efficiency (quenching / binding constant),
the dipeptides had similar accessibility of the tryptophan
residues in the proteins.Circular dichroism (CD)
The effect of binding of these compounds on the
secondary structure of the protein has been determined
through far-UV circular dichroism (CD). The CD spectra
for HSA (Figure 6) observed in the range 200–250
nm reveal the presence of two bands at ~209 nm
and ~222 nm, typically characteristic of α-helicity as
consistent with the literature. Binding of the com-
pounds (1A, 1B, 1C and 1D) to the proteins resulted
in slight change in the secondary structure of theFigure 6 Representative circular dichroism spectra of HSA in
presence of different concentrations of compound 1A. The
black color line indicates the spectrum of HSA (4 μM), the red, green
and blue color line indicate the spectrum of HSA after addition of
4 μM, 8 μM and 16 μM of compound 1A respectively.
Table 3 Thermodynamic parameter of binding as
obtained from molecular docking simulation experiments
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(Figure 6).
Computational chemistry and molecular modeling
studies. BSA and HSA are the major carrier proteins of
the serum. These proteins bind to a variety of small mol-
ecules, mostly non-specifically, and can strongly affect
the way they are delivered through the body. Fluores-
cence perturbation experiments show that the com-
pounds bind very well with serum albumins, which is
also corroborated by docking experiments. Docking of a
ligand into a protein binding site and estimating the
binding affinity of the resulted complex allow under-
standing the interaction pattern of a small molecule at
the binding site. This information provides vital clues to
design structure-based drug molecules. Docking
analysis in the current investigation carried out to
theoretically evaluate the ability of the compounds
to bind serum albumins and the binding site of the
receptor. Negative binding energy for the docked
conformations (Figure 7A and 7C) indicates that the
binding was thermodynamically favourable. BindingFigure 7 Energy spectrum distribution of the bound conformations fo
docking simulations were arranged according to their binding energy. Very
interaction. Binding of 1C and 1D with both the HSA and BSA were found
energy binding modes suggests nonspecificity. Clustering of the bound co
standard deviation and 0.5 kcal mol-1 energy tolerance levels were clustere
significant clustering was observed again suggesting no specificity in bindifree energies for the best docked conformations are
listed in Table 3. Here, each docking experiment was
a composite of 100 independent iterations producing
hundred best docked conformations all of which
were arranged according to their binding energy in
Figure 7A and 7C. In all the cases, the low energy
binding modes indicate thermodynamically favourable
interaction. Binding of 1C and 1D with the serum
albumins appears to be slightly better than that of 1A
and 1B. However, no such narrow discriminationr HSA (A) and BSA (C). All the best output from 100 independent
low energy conformations indicate thermodynamically favorable
to be better than that of 1A and 1B. But the inconsistency in the low
nformations for HSA (B) and BSA (D). Binding modes within 2 Å
d together. Although the low energy binding modes are prevalent no
ng.
Figure 8 Ribbon representation of HSA (A) and BSA (C) docked with best binding modes of all ligands along with the close up views,
(B) and (D) respectively. Ribbons are colored in rainbow; blue to red encompassing N-terminal to C-terminal of the proteins. 1A, 1B, 1C and 1D
are shown in stick models colored in green, magenta, light blue and cyan respectively. In case of HSA best binding modes are found to be in the
domain I and for BSA best binding modes clustered in between the domain I and III.
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Specificity of binding can be shown in terms of
reproducibility of the docked conformation of the
compounds. The docked conformations within 2 Å
standard deviation and 0.5 kcal mol-1 energy tolerance
levels were grouped together into a cluster. Despite of
the thermodynamically favorable interaction docking
outcomes for each experiment showed no cluster
formation (Figure 7B and 7D). Thus, the lack of
reproducibility of the docked conformations within 2
Å standard deviation in space, suggests that the
binding was nonspecific in nature. The best docked
conformations are shown in Figure 8. For HSA the
best docked conformation show that these com-
pounds bind in the domain I and in case of BSA
they bind between domain I and III. Serum albumins
have many fatty acid binding sites. Seven such sites
are reported for HSA, of which one site lies in
domain I [34].
Domain I also binds to other drug molecules such
as, 2,3,5-triiodobenzoic acid [35]. Small molecules are
also reported to bind in to a site in between the
domain I and III of HSA [34]. The major contributing
forces involved in the binding of these compounds with
serum albumins are hydrogen bonding (Additional file 1:
Figure S4 and Additional file 1: Figure S5), hydrophobic
interaction and van der Waals attraction.Conclusion
In conclusion, in this work, we have synthesized four
dipeptides made of cystine amino acid (both protected
and unprotected form) and studied their interaction with
BSA and HSA. Routine solution phase synthesis was
employed to prepare these peptides. The cell viability of
these compounds was quantified by MTT assay. They
show anticancer activity in sub micro molar range. The
phase contrast images show massive cell death. The
interaction between these compounds with HSA and
BSA was investigated by employing different spectro-
scopic techniques (fluorescence and CD spectroscopy).
Fluorescence study indicates strong binding of these
compounds with both BSA and HSA. The CD results
revel that the secondary structure of BSA and HSA
were very slight affected upon interaction with these
compounds. The molecular modeling studies show
that the binding of these compounds with BSA and
HSA are thermodynamically favorable and no cluster
formation occurs, which suggest that the bindings are
nonspecific in nature. Although detail mechanistic
studies of anticancer properties of these molecules are still
going on, the initial results indicate DNA intercalation
(Additional file 1: Figure S6) may be responsible for the
cell death. Further studies in this aspect are going on in
our laboratory and the results will be published in
due course of time.
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characterization data of these molecules, computational method for
partition coefficient (cLogP), detailed mathematical background of
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